Physician profile
Mark N Monroe
NPI 1740244532
$13,124.84
in general payments reported to CMS, 2019-2025
36 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $1,631 · 2021: $2,089 · 2022: $1,441 · 2023: $1,829 · 2024: $1,817 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,134.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,296.95 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $1,131.61 | 2020-2023 | |
| Amgen INC. | $1,127.30 | 2019-2025 | Krystexxa, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,078.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,072.46 | 2020-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $963.90 | 2019-2024 | Xarelto |
| Abbvie INC. | $901.50 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $881.10 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $624.58 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Allergan, INC. | $579.24 | 2019-2020 | |
| Novo Nordisk INC | $554.88 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $391.79 | 2019-2025 | |
| Pfizer INC. | $333.29 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $294.14 | 2019-2023 | |
| Corcept Therapeutics | $261.46 | 2025 | Korlym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.39 | 2020-2022 | |
| Vifor Pharma, INC. | $241.86 | 2019 | |
| Cvrx, INC. | $202.63 | 2025 | Barostim Neo System |
| Astellas Pharma US INC | $126.48 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Abbott Laboratories | $121.01 | 2023-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $84.68 | 2020-2024 | Zoryve |
| Eisai INC. | $64.49 | 2021 | |
| Biogen, INC. | $56.55 | 2025 | Zurzuvae |
| Dexcom, INC. | $46.36 | 2021-2022 | |
| Sanofi Pasteur INC. | $42.74 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.08 | 2020-2021 | |
| Horizon Therapeutics Plc | $36.81 | 2023 | Krystexxa |
| Gilead Sciences, INC. | $34.82 | 2019-2020 | |
| Boston Scientific Corporation | $34.06 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $26.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.93 | 2021 | |
| Edwards Lifesciences Corporation | $22.05 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Paratek Pharmaceuticals, INC. | $18.22 | 2025 | Nuzyra, Xhance |
| Csl Behring | $17.57 | 2019 | |
| Exact Sciences Corporation | $14.59 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.